AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$PGEN

Thomasian Harry Jr. sold $606K of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 100,000 shares of PRECIGEN, INC. (PGEN) at $6.06 ($0.61M total) on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jul 31, 2026, 8:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosure provides a new, timestamped data point on insider selling activity, but it does not include any new company-specific operating, financial, or regulatory catalyst.

02

Market read

Traders may monitor PGEN for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without corroborating fundamentals.

03

What to watch

The article does not state total insider ownership changes beyond the post-transaction share count, nor does it provide sales frequency or prior Form 4 patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31, after-hours SEC Form 4 disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for Precigen, Inc. (PGEN).

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Precigen CFO Thomasian Harry Jr. filed a Form 4 open-market sale of 100,000 shares at $6.06 on 2026-07-31 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other news.

Evidence & confidence

The filing is a routine 10b5-1 planned sale with no accompanying operational or guidance change disclosed in the text.

Market effects

Sector

Minimal. Insider selling in a single biotech does not materially reset sector risk without additional context.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    PRECIGEN, INC.

    Company whose CFO insider sale is disclosed via SEC Form 4.

  • insider
    Thomasian Harry Jr.

    CFO reporting an open-market sale of 100,000 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 4
$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec

SEC EDGAR 8-K6 min
JUN 1
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.

newswise.com4 min
MAY 30
$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis (RRP), presented at the 2026 ASCO meeting. As of April 30, 2026, 15 of 18 complete responders (83%) had ongoing complete responses for ≥36 months without additional RRP treatment; 5 responders had responses beyond 4 years. Precigen said no new adverse safety events were observed. The FDA granted PAPZIMEOS seven-year orphan drug market e

prnewswire.com4 min